| 赵琼瑶,张彩妮.瑞巴派特在Hp阳性胃溃疡患者中的应用研究[J].中国烧伤创疡杂志,2025,(3):239~242. |
| DOI： |
| 中文关键词: 瑞巴派特 幽门螺杆菌 胃溃疡 胃肠激素 炎症 |
| 英文关键词:Rebamipide Helicobacter pylori Gastric ulcer Gastrointestinal hormones Inflammation |
| 基金项目: |
|
| 摘要点击次数: 56 |
| 全文下载次数: 141 |
| 中文摘要: |
| 【摘要】 目的 探讨分析瑞巴派特在幽门螺杆菌 (Hp) 阳性胃溃疡患者中的应用效果。 方法 选取 2021 年 7 月至 2023 年 3 月河南科技大学第一附属医院收治的 82 例 Hp 阳性胃溃疡患者作为研究对象, 并按照不同治疗方法分为试验组 (41 例) 和对照组 (41 例), 试验组患者应用瑞巴派特联合奥美拉唑三联疗法治疗, 对照组患者应用奥美拉唑三联疗法治疗, 比较两组患者血清促胃液素、促胰液素、胆囊收缩素以及白细胞介素-1、白细胞介素-6、C-反应蛋白水平, Hp 根除率和不良反应发生率。 结果 治疗 4 周后, 试验组患者血清促胃液素以及白细胞介素-1、白细胞介素-6、C-反应蛋白水平均明显低于对照组 ( t = 6.696、4.686、3.191、4.151, P<0.001、P<0.001、P= 0.002、P<0.001), 促胰液素和胆囊收缩素水平均明显高于对照组 ( t = 2.712、2.943, P = 0.008、0.004); 治疗 4 周后, 试验组患者 Hp 根除率明显高于对照组 ( χ 2 = 6.011, P = 0.014); 治疗期间, 试验组患者 不良反应发生率明显低于对照组 (χ 2 = 5.513, P= 0.019)。 结论 瑞巴派特可明显改善 Hp 阳性胃溃疡患者胃肠激素分泌水平, 降低炎症反应程度, 提高 Hp 根除率, 且不良反应发生率较低。 |
| 英文摘要: |
| 【Abstract】 Objective To analyze the clinical efficacy of rebamipide in treating patients with Hp?positive gastric ulcer. Methods 82 patients with Hp?positive gastric ulcer admitted to The First Affiliated Hospital of Henan University of Science and Technology from July 2021 to March 2023 were enrolled as research subjects and divided into the experimental group (n = 41) and the control group ( n = 41) based on different treating methods. Patients in the experimental group received rebamipide combined with omeprazole?based triple therapy, whereas patients in the control group were treated with omeprazole?based triple therapy alone. Serum levels of gastrin, secretin, cholecystokinin, interleukin?1, interleukin?6, and C?reactive protein, Hp eradication rates, and incidence of adverse reactions of patients were compared between the two groups. Results After 4 weeks of treatment, the serum levels of gastrin, interleukin?1, interleukin-6, and C-reactive protein of patients in the experimental group were significantly lower than those in the control group ( t = 6.696, 4.686, 3.191 and 4.151, P<0.001, P<0.001, P = 0.002, P<0.001). The levels of secretin and cholecystokinin of patients in the experimental group were significantly higher than that in the control group ( t = 2.712 and 2.943, P = 0.008, P =0.004). After 4 weeks of treatment, Hp eradication rate of patients in the experimental group was significantly higher than that in the control group (χ 2 =6.011, P= 0.014). During the treatment period, the incidence of adverse reactions of patients in the experimental group was significantly lower than that in the control group (χ 2 = 5.513, P= 0.019). Conclusion Rebamipide can significantly improve gastrointestinal hormone secretion levels, decrease inflammatory responses, and increase Hp eradication rate of patients with Hp?positive gastric ulcer, with lower incidence of adverse reactions. |
|
|
|
|
